Loading...
XBKK
MEGA
Market cap771mUSD
Nov 12, Last price  
29.75THB
Name

Mega Lifesciences PCL

Chart & performance

D1W1MN
XBKK:MEGA chart
P/E
13.57
P/S
1.83
EPS
2.19
Div yield, %
5.38%
Shrs. gr., 5y
—
Rev. gr., 5y
2.36%
Revenues
14.15b
-7.80%
4,856,829,2975,964,777,1927,033,531,1017,730,049,0007,944,741,0008,810,230,0009,597,358,00010,341,601,00011,129,783,00012,589,411,00014,135,656,00015,686,224,00015,681,172,00015,344,136,00014,147,389,000
Net income
1.91b
-4.99%
455,892,612555,604,222624,015,532547,880,000695,747,000794,909,0001,112,797,0001,206,008,0001,138,515,0001,392,651,0001,946,825,0002,241,529,0001,992,673,0002,012,481,0001,911,984,000
CFO
2.81b
+16.90%
266,674,335342,019,548465,766,151614,217,000609,122,0001,260,448,000927,002,000919,359,0001,495,106,0001,629,428,0002,726,825,0001,996,625,0001,926,486,0002,401,377,0002,807,103,000
Dividend
Aug 26, 20260.85 THB/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Established in Bangkok, Thailand, in 1982, Mega Lifesciences Public Company Limited, a subsidiary of Unistretch Limited, operates as a comprehensive pharmaceutical and wellness enterprise. Its primary activities encompass the development, promotion, and distribution of a broad spectrum of health-related products, including nutritional supplements, prescription medicines, over-the-counter (OTC) remedies, botanical solutions, vitamins, and everyday consumer goods. The company structures its operations across three main divisions: Brands, Distribution, and Original Equipment Manufacture. Mega Lifesciences offers an extensive array of complementary medicines targeting various health concerns such as bone and joint health, pediatric care, diabetes management, cardiovascular support, digestive and liver wellness, skin health, weight management, overall well-being, men's and women's specific needs, and sports nutrition. Its OTC portfolio addresses common issues like gastrointestinal discomfort and pain. Furthermore, the prescription drug division covers crucial therapeutic areas including iron deficiency, anticoagulation, diabetology, cardiology, dermatology, gastroenterology, neurology, pain relief, osteoporosis, respiratory conditions, urology, oncology, and nephrology. Beyond its proprietary product lines, the company also provides third-party logistical and marketing services. Additionally, Mega Lifesciences is involved in managing wellness centers and offers specialized services in software design, development, and related technological solutions. The company maintains a significant global footprint, with operations spanning the Asia Pacific region, the Middle East, Africa, and the Commonwealth of Independent States.

Key people

Vivek Dhawan
Chief Executive Officer, Executive Director, Chief Coach · since 2013
Thomas Abraham
Chief Financial Officer, Executive Director, Head Coach · since 2013
Paramjit Sawhney
President - International, Head Coach · since 2000
Duangnapha Tongsiri
President - Thailand Mega We Care, Head Coach · since 1996
Girish Wadhwa
President - Myanmar, Head Coach · since 1998
Manoj Gurbuxani
Deputy Chief Financial Officer · since 2020
Sujintana Boonworapat
Company Secretary · since 2000
Non-Executive Director · since 2022
Sameera Shah
Non-Executive Director · since 2022
Non-Executive Director · since 2022
Non-Executive Director · since 2022
Yim Kam Chi
Independent Vice Chairman of the Board · since 2022
Vijay Karwal
Independent Director · since 2021
Thor Santhisiri
Independent Director · since 2013
Nithinart Sinthudeacha
Independent Director · since 2023
Mechai Viravaidya
Independent Chairman of the Board · since 2013
IPO date
Nov 19, 2013
Employees
Domiciled in
TH
Incorporated in
TH

Valuation

Title
THB in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT